Optimising Treatment in Relapsed, Refractory Multiple Myeloma

European Oncology and Haematology · Published 2018-01-01 · DOI 10.17925/eoh.2018.14.2.96

Authors being retrieved — see the publisher record. https://doi.org/10.17925/eoh.2018.14.2.96

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2018

Related articles

• Midostaurin for FLT3-mutated Acute Myeloid Leukaemia – Considerations for Optimal Use · European Oncology and Haematology · 2019 · Same journal
• Thromboprophylaxis – A Neglected Front in Hospitalised Patients with COVID-19 in Pakistan · European Oncology and Haematology · 2020 · Same journal
• Immunotherapy in Advanced Prostate Cancer · European Oncology and Haematology · 2020 · Same journal
• Expert Opinion on the Treatment of Refractory Chronic Phase Chronic Myeloid Leukaemia · European Oncology and Haematology · 2017 · Same journal
• Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study · European Oncology and Haematology · 2019 · Same journal
• Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma · European Oncology and Haematology · 2017 · Same journal
• More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer · European Oncology and Haematology · 2018 · Same journal
• Shaping Macrophage Plasticity with Iron – Towards a New Therapeutic Approach · European Oncology and Haematology · 2018 · Same journal
• Epigenetics in the Biology and Treatment of Multiple Myeloma · European Oncology and Haematology · 2016 · Same journal
• Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study · European Oncology and Haematology · 2019 · Same journal